Form 8-K GALECTIN THERAPEUTICS For: Nov 10
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil slides following outreach to Iran to limit Houthis actions in Red Sea
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Galectin Therapeutics (GALT) Tops Q3 EPS by 10c
November 10, 2014 8:14 AM ESTGalectin Therapeutics (NASDAQ: GALT) reported Q3 EPS of ($0.17), $0.10 better than the analyst estimate of ($0.27).
The Company also provided an update on its development program.
According to Peter Traber, M.D., Chief Executive Officer, President and Chief Medical Officer, Galectin Therapeutics, "In the past three months, we have continued progress in our development program. We were pleased to have data from cohorts 1 and 2, as well as, interim data from nine completed patients from cohort 3 of our Phase 1 clinical trial of GR-MD-02, our patent-protected proprietary galectin inhibitor, in patients with NASH with advanced... More
